Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17541649 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30424032 | 0.84 | HSP90AA1 (0.40) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1235136 | 0.84 | HSP90AA1 (0.40) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16149260 | 0.84 | CYP2C9 (0.44) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL25289588 | 0.81 | CYP2C9 (0.39) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3757830 | 0.81 | CACNA1B (0.41) | ALDH1A1MAPK1SMN1; SMN2KMT2ACYP2C9 | |
| SCHEMBL30496249 | 0.81 | CYP2C9 (0.39) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30430258 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1085042 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31664072 | 0.80 | ATR (0.44) | CYP2C9CYP2C19NPSR1LCKATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-27 | — | — | US | disclosed |
| US-20180222901-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20180222901-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
| EP-3334741-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| US-9655889-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655889-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655889-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| EP-2970273-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-2970273-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| WO-2017025913-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| EP-3114129-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-11 | — | — | EP | disclosed |
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409922-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2970273-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160000771-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000771-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| WO-2015126751-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| WO-2014164409-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222901-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | MAVS, EIF2AK2, ITPA | ALDH1A1 2086/4885MAPK1 451/4885SMN1; SMN2 3459/4885 |
| US-20160000771-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | ALDH1A1 3508/4885MAPK1 1620/4885SMN1; SMN2 3068/4885 |
| US-20150232480-A1 | Imidazopyridine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, MAVS, TYMP | ALDH1A1 3105/4885MAPK1 967/4885SMN1; SMN2 2620/4885 |
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, CCNI | ALDH1A1 1756/4885MAPK1 2140/4885SMN1; SMN2 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.